Slide background
Slide background




Safe design and operation of on site generation of oxygen 93% for medical use

ID 1668 | | Visite: 7511 | Documenti Chemicals EntiPermalink: https://www.certifico.com/id/1668



Safe design and operation of on site generation of oxygen 93% for medical use

Oxygen for medicinal use is a prime requirement for all healthcare facilities for both the treatment of patients with respiratory disease and for providing additional oxygen to patients being treated within the facility.

For those hospitals and clinics, where the demand is higher, oxygen is normally distributed throughout the facility using a medical gas pipeline system.

The design requirements for the supply source used to supply medical oxygen to the pipeline system are detailed in the standard, EN ISO 7396-1 Medical gas pipeline systems; Pipeline systems for compressed medical gases and vacuum.

Two different products are included in the standard:

- Medicinal oxygen supplied from liquid oxygen vessels and/or gaseous oxygen cylinders; and
- Oxygen 93 manufactured on-site within the healthcare facility, using an oxygen concentrator unit.

Medicinal oxygen supplied either in cylinders or as a cryogenic liquid, is required to be manufactured by an approved supplier with a manufacturers licence (to demonstrate compliance with guidelines detailed in the European Commission’s Guide to Good Manufacturing Practice (GMP))

Within the European Union, the supplier of medical oxygen is required to hold a marketing authorisation in accordance with Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, detailing the clinical indications and contraindications and specific warnings for the safe use of the product.

The specification of this medical oxygen is detailed in the European Pharmacopoeia monograph for medical oxygen, which specifies a minimum purity of 99.5% oxygen.

The quality, safety and efficacy of the medical oxygen are ensured by the medical gas supplier through a quality management system under the responsibility of a qualified person.

Oxygen 93 can be manufactured on-site within the healthcare facility, under the responsibility of the healthcare facility pharmacist, using an oxygen 93 supply system and meeting the appropriate and specific quality and safety criteria for medicinal products prepared in Pharmacies (see Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide PE010-4 Guideline to good practices for the preparation of medicinal products in healthcare establishment).

Oxygen 93 is not being ‘put on the market’, so it currently falls outside the regulation for the manufacture and supply of medicinal product Directive 2001/83/EC.

Oxygen 93 concentrator units are covered by the requirements for CE marking in accordance with the Medical Device Directive, (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices).

The specification of the oxygen manufactured using an oxygen 93 supply system is detailed in the European Pharmacopoeia monograph for oxygen 93, which specifies the oxygen content to be between 90% and 96% and gives appropriate limits and analysis methods of other possible contaminants during the production.

As the oxygen 93 is produced by adsorbing the nitrogen from ambient air, the major contaminant in oxygen 93 is argon, which can be present up to 5%.

When the oxygen 93% monograph was introduced it was stated that the benefits of PSA oxygen (oxygen 93 per cent) are to allow production and supply of oxygen at sites where access for cylinder and liquid oxygen supply is difficult or impossible. PSA concentrators are in use in a number of fields particularly by the military (field hospitals).

The quality of the gas is very much dependent upon the performance of the equipment that produces it.

At the time of preparation of this publication, oxygen 93 is not licensed under a marketing authorisation, thus it is not evaluated by regulatory authorities and thus it cannot be considered as “equivalent medicine” for the oxygen.

EIGA 2015

Descrizione Livello Dimensione Downloads
Allegato riservato Safe Design and Operation On Site Generation Oxygen 93 for Medical Use.pdf
EIGA 2015
291 kB 16

Tags: Chemicals EIGA

Articoli correlati

Ultimi archiviati Chemicals

ECHA Annual report 2024
Apr 19, 2025 332

ECHA Annual report 2024

ECHA Annual report 2024 ID 23848 | 19.04.2025 / Attached ECHA’s achievements in 2024 reflect a strong commitment to our strategic goals and priorities, as well as our vision of chemical safety through science, collaboration and knowledge. We continued to progress and implement our existing legal… Leggi tutto
Piano nazionale di controllo ufficiale degli additivi e aromi alimentari 2025 2027
Apr 17, 2025 408

Piano nazionale di controllo ufficiale degli additivi e aromi alimentari 2025-2027

Piano nazionale di controllo ufficiale degli additivi e aromi alimentari 2025-2027 ID 23839 | 17.04.2025 / In allegato Piano nazionale di controllo ufficiale degli additivi e aromi alimentari come materia prima e negli alimenti comprese le sostanze aromatizzanti di affumicatura anni 2025-2027 Il… Leggi tutto
Apr 08, 2025 722

Decreto 27 marzo 2025 | Suppl. 11.7 Farmacopea europea 11ª ed.

Decreto 27 marzo 2025 | Suppl. 11.7 Farmacopea europea 11ª ed. ID 23772 | 08.04.2025 Decreto 27 marzo 2025 Entrata in vigore dei testi, nelle lingue inglese e francese, pubblicati nel supplemento 11.7 della 11ª edizione della Farmacopea europea. (GU n.82 del 08.04.2025) _________ Art. 1. 1. I testi… Leggi tutto
Apr 07, 2025 735

Regolamento delegato (UE) 2025/687

Regolamento delegato (UE) 2025/687 ID 23761 | 07.04.2025 Regolamento delegato (UE) 2025/687 della Commissione, del 30 gennaio 2025, che modifica il regolamento delegato (UE) 2019/624 per quanto riguarda le ispezioni ante mortem presso i macelli, le ispezioni ante mortem presso l’azienda di… Leggi tutto
Mar 20, 2025 841

Regolamento delegato (UE) 2020/1413

Regolamento delegato (UE) 2020/1413 ID 23662 | 20.03.2025 Regolamento delegato (UE) 2020/1413 della Commissione del 29 giugno 2020 che rettifica la versione in lingua svedese dell’allegato I del regolamento (CE) n. 1272/2008 del Parlamento europeo e del Consiglio relativo alla classificazione,… Leggi tutto
IARC Monograph Volume 58
Mar 17, 2025 845

IARC Monographs Volume 58 / 1993

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 58 / IARC 1993 ID 23643 | 17.03.2025 / Attached Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry Evaluates the carcinogenic risk to humans posed by exposure to selected metals and their compounds.… Leggi tutto
Mar 14, 2025 1037

Regolamento (UE) 2024/2929

Regolamento (UE) 2024/2929 ID 23634 | 14.03.2025 Regolamento (UE) 2024/2929 della Commissione, del 27 novembre 2024, che rettifica la versione in lingua francese dell’allegato XVII del regolamento (CE) n. 1907/2006 del Parlamento europeo e del Consiglio per quanto riguarda i livelli di… Leggi tutto
Microbioma nell uomo negli animali negli alimenti e nell ambiente
Mar 14, 2025 801

Microbioma nell’uomo, negli animali, negli alimenti e nell’ambiente

Microbioma nell’uomo, negli animali, negli alimenti e nell’ambiente / Rapporto ISTISAN 2025 ID 23627 | 14.03.2025 / In allegato (EN) Microbioma nell’uomo, negli animali, negli alimenti e nell’ambiente: implicazioni per la valutazione del rischio nella sicurezza alimentare. L’Autorità Europea per la… Leggi tutto

Più letti Chemicals

Notifica HACCP
Apr 05, 2022 98556

Notifica ai fini registrazione Regolamento CE n. 852/2004

Notifica ai fini della registrazione (Reg. CE n. 852/2004) - Ex notifica sanitaria alimentare ID 7901 | 06.03.2019 / Modello notifica allegato [panel]Regolamento (CE) 852/2004...Articolo 6 Controlli ufficiali, registrazione e riconoscimento 1. Gli operatori del settore alimentare collaborano con le… Leggi tutto